Empaglo 25 mg (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
(Co., Ltd.) White Life Sciences
MFDS item code 202106163 · Approved 2021.08.25
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to assist in blood sugar control in adults with type 2 diabetes who have difficulty managing glucose levels with diet and exercise. It may be administered alone or in combination with other drugs, effectively improving blood sugar levels. In particular, for diabetic patients with a history of cardiovascular disease, additional guidance from a specialist should be referenced regarding the risk of cardiovascular events. This medication helps manage the patient's blood sugar and contributes to the prevention of complications related to diabetes.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent eGFR of less than 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the eGFR decreases to less than 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those receiving dialysis, as efficacy is not expected. No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. No dose adjustment is necessary based on age. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered. Initiation of this medicine is not recommended in patients aged 85 years and older because clinical experience is limited.
This medication should not be used by individuals with an allergic reaction to the active ingredient or any excipients. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Patients with severely reduced kidney function, specifically those with a glomerular filtration rate of less than 30 mL/min/1.73m2, those with end-stage renal disease, or those undergoing dialysis should not use this medication. As this medication contains lactose, it should not be administered to patients with lactose intolerance, galactose intolerance, or genetic lactase deficiency. Caution should be exercised in using this medication in patients with decreased kidney function, and it is particularly advised not to initiate treatment in those with a glomerular filtration rate of less than 60 mL/min/1.73m2, and to discontinue treatment if it falls below 45 mL/min/1.73m2. In cases of severe heart failure, use of this medication is not recommended and care should be taken. When used in conjunction with insulin or sulfonylureas, there may be a risk of hypoglycemia, necessitating dosage adjustments. This medication can cause various adverse reactions, such as hypoglycemia, genital infections, urinary tract infections, increased urination, fluid loss, and elevated serum creatinine levels, so symptoms should be closely monitored. In particular, serious metabolic acidosis known as ketoacidosis may occur, and if symptoms (nausea, vomiting, abdominal pain, difficulty breathing, etc.) arise, immediate treatment should be sought. Elderly patients or those at risk of fluid loss should be vigilant for dehydration and hypotension, and regular monitoring of fluid status is important. This medication may increase the risk of serious infections such as urosepsis, pyelonephritis, and necrotizing fasciitis, so if signs of infection occur, immediate consultation with healthcare professionals is necessary. Use of this medication is not recommended during pregnancy, and it should be discontinued if pregnancy is confirmed. When breastfeeding, it is also safest to discontinue breastfeeding as this medication may be excreted in breast milk. Safety and efficacy in children under 18 years have not been established, and it should not be used in this population. In cases of overdose, clinical status should be closely monitored, and appropriate treatment should be administered. This medication should be stored out of reach of children and should not be transferred to other containers for safety. Caution is needed when driving or operating machinery due to the risk of hypoglycemia. Diabetic patients should pay attention to routine foot care and be cautious about the risk of limb amputation.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained between 1 and 30 degrees Celsius to ensure the drug's efficacy remains safely intact for a long time.
Pale yellow oval film-coated tablet
30 tablets/PTP (10 tablets/PTP × 3), 10 tablets/PTP (10 tablets/PTP × 1)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 25mg
Tablet · Prescription medication
(Co., Ltd.) White Life Sciences

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.